Clear all
Content type:
Bimekizumab Efficacy and Safety in Biologic DMARD-Naïve Patients with Psoriatic Arthritis was Consistent With or Without Methotrexate: 52-Week Results from the Phase 3 Active Reference Study BE OPTIMAL
McInnes B. Iain, Mease J. Philip, Tanaka Yoshiya, et al.
Bimekizumab maintenance of response and safety in patients with moderate to severe plaque psoriasis: Results from the open-label extension period (Weeks 48–144) of the BE RADIANT phase 3b trial
Strober Bruce, Puig Luis, Blauvelt Andrew, et al.